The use of low-dose mitomycin C for prevention of recurrent pterygium

Ophthalmology. 1994 Apr;101(4):759-62. doi: 10.1016/s0161-6420(94)31269-3.

Abstract

Background: The administration of high doses of topical mitomycin C after pterygium excision causes a variety of complications.

Methods: Seventy-five patients who had advanced or recurrent pterygia underwent excision of pterygia, leaving the sclera bare. Patients were randomized in a masked fashion into three groups of 25 patients each. Patients in group 1 received topical 0.01% mitomycin C for 5 days, patients in group 2 received 0.02% mitomycin C for 5 days, and those in group 3 were treated with 1200 rad beta-irradiation. Patients were followed by a surgeon who was masked to the patient treatment. The mean follow-up period was 15.3 months.

Results: The recurrence rate after pterygium surgeries was 8% in group 1, 4% in group 2, and 20% in group 3. There were no statistical differences between the study groups. Delay of epithelialization for 8 weeks in one patient and degenerative calcification of conjunctiva 18 months after surgery in another patient, both from group 2, were the only complications in this study.

Conclusion: This study indicates the advantage of 0.01% mitomycin C for post-operative prevention of recurrence of pterygium.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Mitomycin / therapeutic use*
  • Ophthalmic Solutions
  • Postoperative Complications / prevention & control
  • Pterygium / prevention & control*
  • Pterygium / radiotherapy
  • Pterygium / surgery
  • Recurrence

Substances

  • Ophthalmic Solutions
  • Mitomycin